"No turning bax" in the combined battle against prostate cancer: Commentary on Khor et al., p. 3585

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3435-3438

  Rajendran, Ramji R ^a   Kao, Gary D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CLINICAL TRIALS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 34250790302     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0810     Document Type: Note

References (32)

1. Khor L-Y, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group Protocol 92-02. Clin Cancer Res 2007;13:3585-90.
2. Jemal AR, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Freedland SJ, Partin AW. Prostate-specific antigen: update 2006. Urology 2006;67:458-60.
4. Speight JL, Roach M III. Advances in the Treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 2007;25:987-95.
5. Walter LC, Bertenthal D, Lindquist K. PSA screening among elderly men. JAMA 2006;296:2336-42.
6. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007;177:505-9.
7. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35.
8. DiPaola RS, Thompson IM. National cooperative group trials. Urology 2005;65:23-9.
9. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;1:3210-6.
10. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JL. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
11. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-7.
12. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006;54:85-90.
13. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7.
14. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
15. Friedrich MJ. Researchers probe consequences of androgen deprivation for prostate cancer. JAMA 2006;296:2305-6.
16. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61:32-8.
17. Roach M 3rd. Hormonal therapy and radiotherapy for localized prostate cancer who, where and how long? J Urol 2003;170:S35-40.
18. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
19. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
20. Cho YS, Kim M-K, Tan L, Srivastava R, Agrawal S, Cho-Chung YS. Protein kinase AR Iα antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res 2002;8:607-14.
21. Yamanaka K, Rocchi P, Miyake H, et al. An ovel anti-sense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005;4:1689-98.
22. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
23. Kyprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-8.
24. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 1998;37:223-9.
25. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense oligodeoxynucleotides. Urology 1999;54:36-46.
26. Lin Y, Kokontis J, Tang F, et al. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006;26:1908-16.
27. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. BCL-2/BAX ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998;52:1085-90.
28. Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 2001;165:2126-30.
29. Gazzaniga P, Gradilone A, Vercillo R, et al. Bcl-2/bax mRNAe xpression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996;69:100-4.
30. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-66.
31. Sjostrom J, Blomqvist C, von Boguslawski K, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8:811-6.
32. Guzzo TJ, Vira M, Wang Y, et al. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol 2006;175:518-21.